Effect of Nucleic Acid Amplification Testing on Population-Based Incidence Rates of Clostridium difficile Infection
Clinical Infectious Diseases2013Vol. 57(9), pp. 1304–1307
Citations Over TimeTop 10% of 2013 papers
Carolyn V. Gould, Jonathan R. Edwards, Jessica Cohen, Wendy Bamberg, Leigh Anne Clark, Monica M. Farley, Helen Johnston, Joelle Nadle, Lisa G. Winston, Dale N. Gerding, L. Clifford McDonald, Fernanda C. Lessa, Zintars G. Beldavs, Sammy A. Hanna, Gary E. Hollick, Stacy Holzbauer, Carol A. Lyons, Erin C. Phipps, Lucy Wilson
Abstract
Nucleic acid amplification testing (NAAT) is increasingly being adopted for diagnosis of Clostridium difficile infection (CDI). Data from 3 states conducting population-based CDI surveillance showed increases ranging from 43% to 67% in CDI incidence attributable to changing from toxin enzyme immunoassays to NAAT. CDI surveillance requires adjustment for testing methods.
Related Papers
- → Effect of Nucleic Acid Amplification Testing on Population-Based Incidence Rates of Clostridium difficile Infection(2013)105 cited
- → <i>Clostridium difficile</i> Toxin B: Insights into Its Target Genes(2022)1 cited
- → Molecular methods in the diagnosis ofClostridium difficileinfections: an update(2013)8 cited
- → [Infection rate and clinical characteristics of toxigenic Clostridium difficile in children with inflammatory bowel disease].(2020)3 cited
- → Surgical-site infection with toxin A-nonproducing and toxin B-producing Clostridium difficile(2008)6 cited